Document is current
Any future updates will be listed below
-
Authors
Than, Hein
Pomicter, Anthony D.
Yan, Dongqing
Beaver, Larry P.
Eiring, Anna M. http://orcid.org/0000-0001-6533-9150
Heaton, William L.
Senina, Anna
Clair, Phillip M.
Shacham, Sharon
Mason, Clinton C. http://orcid.org/0000-0002-9566-4568
Hare, Thomas O’
Deininger, Michael W. http://orcid.org/0000-0002-2987-1331
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01CA178397)
- License Information
-
More Information
Article History
Received: 2 April 2019
Revised: 4 December 2019
Accepted: 14 January 2020
First Online: 24 January 2020
Compliance with ethical standards
:
: MWD is on the advisory board and is a consultant for Incyte, Novartis and Pfizer, and serves on the advisory board for Takeda, Blueprint and Galena BioPharma. His laboratory receives research funding from Novartis and Pfizer. SS is the President and Chief Scientific Officer of Karyopharm Therapeutics.
